全文获取类型
收费全文 | 2416篇 |
免费 | 187篇 |
国内免费 | 261篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 20篇 |
妇产科学 | 26篇 |
基础医学 | 328篇 |
口腔科学 | 29篇 |
临床医学 | 187篇 |
内科学 | 253篇 |
皮肤病学 | 28篇 |
神经病学 | 140篇 |
特种医学 | 79篇 |
外国民族医学 | 4篇 |
外科学 | 158篇 |
综合类 | 665篇 |
预防医学 | 28篇 |
眼科学 | 69篇 |
药学 | 428篇 |
中国医学 | 11篇 |
肿瘤学 | 401篇 |
出版年
2023年 | 17篇 |
2022年 | 28篇 |
2021年 | 52篇 |
2020年 | 35篇 |
2019年 | 31篇 |
2018年 | 30篇 |
2017年 | 23篇 |
2016年 | 21篇 |
2015年 | 29篇 |
2014年 | 54篇 |
2013年 | 192篇 |
2012年 | 79篇 |
2011年 | 110篇 |
2010年 | 86篇 |
2009年 | 104篇 |
2008年 | 131篇 |
2007年 | 165篇 |
2006年 | 247篇 |
2005年 | 244篇 |
2004年 | 213篇 |
2003年 | 208篇 |
2002年 | 165篇 |
2001年 | 145篇 |
2000年 | 124篇 |
1999年 | 90篇 |
1998年 | 58篇 |
1997年 | 48篇 |
1996年 | 42篇 |
1995年 | 35篇 |
1994年 | 19篇 |
1993年 | 8篇 |
1992年 | 11篇 |
1991年 | 9篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1981年 | 1篇 |
排序方式: 共有2864条查询结果,搜索用时 15 毫秒
21.
BackgroundOligonucleotides belong to a class of macromolecules with great potential for research and various therapeutic applications. Their mechanisms of action are extremely diverse, although they are rather homogeneous in composition. Single-stranded oligodeoxynucleotides are not only inhibitors of gene expression, but their CpG sequence motifs may activate the innate immune response. Recent progress made in preclinical and clinical testing, as well as the case of the most recently discovered RNA interference technology, will help to overcome efficacy problems of the previous approaches of the ‘standard therapy’ of such diseases as tumors and various infections.MethodsThe aim of this article is to present various therapeutic aspects of oligonucleotides, and to review the most significant therapeutic applications of synthetic oligonucleotides. This paper presents a comprehensive review of current literature on various therapeutic properties of synthetic oligonucleotides.ConclusionsThe available results gathered from preclinical and clinical studies suggest that TLR9-targeted therapy of oligonucleotides can stimulate both innate and adaptive immunity. It also appears that CpG ODNs are generally safe, although moderate adverse effects, based on a backbone-related mechanism have been reported. The presented studies demonstrate that adjuvant CpG ODN can unify an immune response that leads to enhanced antigen-specific Ab formation. CpG ODN may therefore provide a unique approach to enhancing the efficacy of immunization, including the strengthening of antitumor immunity. 相似文献
22.
《Expert opinion on therapeutic targets》2013,17(3):241-253
The inhibitor of apoptosis (IAP) genes have emerged as probably the most important intrinsic regulators of apoptosis. The members of the IAP family are highly conserved in evolutionarily distant species and perform the critical role of binding to and inhibiting distinct caspases. This inhibition is mediated by discrete baculoviral IAP repeat domains that, in a domain-specific manner, inhibit either the initiator or executioner caspases. As such the function of IAPs lies at the very centre of virtually all apoptotic pathways. Since many, if not most, human pathologies involve aberrant apoptosis, the modulation of IAP levels or their activity offers huge therapeutic potential for treatment of various disorders. Indeed, available data suggest that the therapeutic downregulation of IAPs by antisense targeting or their adenovirally-mediated overexpression, can in fact be used to successfully modulate cell death. 相似文献
23.
《Expert opinion on investigational drugs》2013,22(12):2059-2088
For decades, cancer therapy has focused on DNA-directed mechanisms of cytotoxicity, utilising agents with limited efficacy and significant toxicity. Recent advances in tumour biology have elucidated the molecular pathways implicated in the pathogenesis and progression of cancers and have resulted in the discovery of a variety of novel molecular targets for therapeutic intervention. Promising novel agents targeting signal transduction pathways, cell cycle regulation, angiogenesis and apoptosis are in clinical testing and are discussed in this review. 相似文献
24.
25.
26.
27.
28.
29.
《Drug delivery》2013,20(4):220-231
Both antisense oligonucleotides (ASODN) and small interfering RNA (siRNA) have enormous potential to selectively silence specific cancer-related genes and could therefore be developed to be important therapeutic anti-cancer drugs. The use of nanotechnology may allow for significant advancement of the therapeutic potential of ASODN and siRNA, due to improved pharmacokinetics, bio-distribution and tissue specific targeted therapy. In this mini-review, we have discussed the advantages of using a nanocarrier such as a multimodal quantum rod (QR) complexed with siRNA for gene delivery. Comparisons are made between ASODN and siRNA therapeutic efficacies in the context of cancer and the enormous application potential of nanotechnology in oncotherapy is discussed. We have shown that a QR-interleukin-8 (IL-8) siRNA nanoplex can effectively silence IL-8 gene expression in the PC-3 prostate cancer cells with no significant toxicity. Thus, nanocarriers such as QRs can help translate the potent effects of ASODN/siRNA into a clinically viable anti-cancer therapy. Drug delivery for cancer therapy, with the aid of nanotechnology is one of the major translational aspects of nanomedicine, and efficient delivery of chemotherapy drugs and gene therapy drugs or their co-delivery continue to be a major focus of nanomedicine research. 相似文献
30.
《Expert opinion on investigational drugs》2013,22(6):1197-1205
Although the standard approach to myeloid leukaemias remains chemotherapy, the agents currently available rarely result in cure. Recent advances in understanding the biology of these disorders have lead to the development of targeted treatment strategies. In acute promyelocytic leukaemia (APL), all-trans retinoic acid (ATRA), sodium phenylbutyrate and arsenic trioxide are agents which either induce differentiation or apoptosis and have been used to successfully achieve remission. The tyrosine kinase inhibitor, STI-571, antisense oligonucleotides, and bcr-abl vaccines are strategies which focus on the oncogenic events in chronic myelogenous leukaemia (CML). Two anti-CD33 monoclonal antibody conjugates, Y90-HuM195 and CMA-676, have been used in acute myelogenous leukaemia (AML) and have shown some efficacy. Although the preliminary results with these targeted therapies are promising, further studies are needed to establish them as effective, less toxic alternatives to the current standard of care. 相似文献